Non-Small Cell Lung Cancer Market Size, Share, Trends, & Industry Analysis Report By Type, By Treatment (Chemotherapy, Targeted Therapy, Immunotherapy, and Others), By Distribution Channel, and By Region – Market Forecast, 2025–2034

The non-small cell lung cancer market size is expected to reach USD 129.88 Billion by 2034, according to a new study by Polaris Market Research. The report “Non-Small Cell Lung Cancer Market Share, Size, Trends, Industry Analysis Report: By Type, By Treatment (Chemotherapy, Targeted Therapy, Immunotherapy, and Others), By Distribution Channel, and By Region; Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Non-small cell lung cancer (NSCLC) represents the majority of global lung cancer cases and is driving advances in precision oncology. Increasing use of biomarker testing, targeted therapies, and immunotherapies is reshaping treatment approaches, while innovations in liquid biopsy and mutation-specific drugs are enabling earlier diagnosis and better outcomes.

Market growth is primarily driven by the rising global incidence of NSCLC, increasing adoption of targeted and immune-based therapies and the growing availability of companion diagnostics that support personalized treatment plans.

Non-Small Cell Lung Cancer Market Report Highlights

Based on type, the adenocarcinoma segment dominated the market share in 2024, driven by its high prevalence and strong response to targeted therapy options.

In terms of treatment, the targeted therapy segment dominated the market in 2024, supported by the broad clinical use of EGFR, ALK, and KRAS inhibitors.

Based on distribution channel, the hospital pharmacy segment dominated the market in 2024, due to centralized access to advanced oncology drugs and clinical oversight.

North America accounted for the majority share in the global non-small cell lung cancer market in 2024, driven by early adoption of molecular diagnostics and regulatory support for novel therapies.

Asia Pacific is projected to grow at the fastest CAGR during the forecast period, owing to rising cancer incidence, expanding healthcare access, and growing investment in oncology research.

A few global key market players include Roche Holding AG, AstraZeneca PLC, Merck & Co., Inc., Bristol-Myers Squibb Company, Pfizer Inc., Eli Lilly And Company, Novartis AG, Johnson & Johnson, Amgen Inc., Beigene Ltd., Exelixis Inc., and Mirati Therapeutics Inc.

Polaris Market Research has segmented the market report on the basis of type, treatment, distribution channel, and region:

By Type Outlook (Revenue, USD Billion, 2020–2034)

Squamous Cell Carcinoma

Large Cell Carcinoma

Adenocarcinoma

Other Type

By Treatment Outlook (Revenue, USD Billion, 2020–2034)

Chemotherapy

Targeted Therapy

Immunotherapy

Others

By Distribution Channel Outlook (Revenue, USD Billion, 2020–2034)

Hospital Pharmacy

Drug Store and Retail Pharmacy

Online Pharmacy

By Regional Outlook (Revenue, USD Billion, 2020–2034)

North America

US

Canada

Europe

Germany

France

UK

Italy

Spain

Netherlands

Russia

Rest of Europe

Asia Pacific

China

Japan

India

Malaysia

South Korea

Indonesia

Australia

Vietnam

Rest of Asia Pacific

Middle East & Africa

Saudi Arabia

UAE

Israel

South Africa

Rest of Middle East & Africa

Latin America

Mexico

Brazil

Argentina

Rest of Latin America Show more